Category: General

LitAlert ~~ GeneLit.com

    • Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.
    • Mihajlovich Tsyganov MM, Ibragimova MK, Garbukov EY, Bragina OD, Karchevskaya AA, Usynin EA, Litvyakov NV.
    • Int J Mol Sci. 2022 Dec 22;24(1):207. doi: 10.3390/ijms24010207.

    • Clinical Cancer and Direct-to-Consumer Genetic Test Result-Sharing Behavior: Findings from HINTS 2020.
    • Makhnoon S, Yu R, Peterson SK, Shete S.
    • J Pers Med. 2022 Dec 22;13(1):18. doi: 10.3390/jpm13010018.

    • Cancer prevention in cancer predisposition syndromes: A protocol for testing the feasibility of building a hereditary cancer research registry and nurse navigator follow up model.
    • Etchegary H, Pike A, Puddester R, Watkins K, Warren M, Francis V, Woods M, Green J, Savas S, Seal M, Gao Z, Avery S, Curtis F, McGrath J, MacDonald D, Burry TN, Dawson L.
    • PLoS One. 2022 Dec 22;17(12):e0279317. doi: 10.1371/journal.pone.0279317.

    • LitAlert ~~ GeneLit.com

    • Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    • Herzog TJ, Vergote I, Gomella LG, Milenkova T, French T, Tonikian R, Poehlein C, Hussain M.
    • Eur J Cancer. 2023 Jan 1;179:136-146. doi: 10.1016/j.ejca.2022.10.021. Epub ahead of print.

    • Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study.
    • Taji T, Odan N, Kataoka Y, Ikeda M, Yamaguchi A, Suzuki E, Suwa H.
    • Breast Cancer. 2022 Dec 22. doi: 10.1007/s12282-022-01424-3. Epub ahead of print.

    • Genetic testing women with newly diagnosed breast cancer: What criteria are the most predictive of a positive test?
    • Metcalfe KA, Narod SA, Eisen A, Poll A, Zamani N, McCready D, Cil TD, Wright FC, Lerner-Ellis J, McCuaig J, Graham T, Sun P, Akbari MR.
    • Cancer Med. 2022 Dec 21. doi: 10.1002/cam4.5515. Epub ahead of print.

    • Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
    • Magliacane G, Brunetto E, Calzavara S, Bergamini A, Pipitone GB, Marra G, Redegallin M, Grassini G, Rabaiotti E, Taccagni G, Pecciarini L, Carrera P, Mangili G, Doglioni C, Cangi MG.
    • Cancers (Basel). 2022 Dec 21;15(1):43. doi: 10.3390/cancers15010043.

    • Fertility Preferences and Practices Among Young Women With Breast Cancer: Germline Genetic Carriers Versus Non-carriers.
    • Lewinsohn R, Zheng Y, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Peppercorn J, Borges VF, Come S, Snow C, Ginsburg ES, Partridge AH.
    • Clin Breast Cancer. 2022 Dec 21:S1526-8209(22)00290-7. doi: 10.1016/j.clbc.2022.12.012. Epub ahead of print.

    Related:

    •• Identifier: NCT01468246: The Young Women's Breast Cancer Study (HOHO). (ClinicalTrials.gov . Accessed 2022 Dec 21.)

    • European Commission Approves Olaparib Plus Abiraterone and Prednisone/Prednisolone for mCRPC.
    • Ryan C.
    • OncLive. 2022 Dec 21.

    • A systematic method for detecting abnormal mRNA splicing and assessing its clinical impact in individuals undergoing genetic testing for hereditary cancer syndromes.
    • Kamps-Hughes N, Carlton VEH, Fresard L, Osazuwa S, Starks E, Vincent JJ, Albritton S, Nussbaum RL, Nykamp K.
    • J Mol Diagn. 2022 Dec 20:S1525-1578(22)00348-8. doi: 10.1016/j.jmoldx.2022.12.002. Epub ahead of print.

    • Pregnancy-Associated Breast Cancer in BRCA1/2 Carriers: Is Intensified Breast Ultrasound Surveillance Warranted?
    • Fruchtman-Brot H, Mango VL.
    • Acad Radiol. 2022 Dec 19:S1076-6332(22)00595-5. doi: 10.1016/j.acra.2022.11.004. Epub ahead of print.
    • Commentary

    • Towards Personalized Management of Ovarian Cancer.
    • Algethami M, Kulkarni S, Sadiq MT, Tang HKC, Brownlie J, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S.
    • Cancer Manag Res. 2022 Dec 15;14:3469-3483. doi: 10.2147/CMAR.S366681.

    • LitAlert ~~ GeneLit.com

    • Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    • Herzog TJ, Vergote I, Gomella LG, Milenkova T, French T, Tonikian R, Poehlein C, Hussain M.
    • Eur J Cancer. 2023 Jan 1;179:136-146. doi: 10.1016/j.ejca.2022.10.021. Epub ahead of print.

    • Genetic testing women with newly diagnosed breast cancer: What criteria are the most predictive of a positive test?
    • Metcalfe KA, Narod SA, Eisen A, Poll A, Zamani N, McCready D, Cil TD, Wright FC, Lerner-Ellis J, McCuaig J, Graham T, Sun P, Akbari MR.
    • Cancer Med. 2022 Dec 21. doi: 10.1002/cam4.5515. Epub ahead of print.

    • Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
    • Magliacane G, Brunetto E, Calzavara S, Bergamini A, Pipitone GB, Marra G, Redegallin M, Grassini G, Rabaiotti E, Taccagni G, Pecciarini L, Carrera P, Mangili G, Doglioni C, Cangi MG.
    • Cancers (Basel). 2022 Dec 21;15(1):43. doi: 10.3390/cancers15010043.

    • Fertility Preferences and Practices Among Young Women With Breast Cancer: Germline Genetic Carriers Versus Non-carriers.
    • Lewinsohn R, Zheng Y, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Peppercorn J, Borges VF, Come S, Snow C, Ginsburg ES, Partridge AH.
    • Clin Breast Cancer. 2022 Dec 21:S1526-8209(22)00290-7. doi: 10.1016/j.clbc.2022.12.012. Epub ahead of print.

    Related:

    •• Identifier: NCT01468246: The Young Women's Breast Cancer Study (HOHO). (ClinicalTrials.gov . Accessed 2022 Dec 21.)

    • European Commission Approves Olaparib Plus Abiraterone and Prednisone/Prednisolone for mCRPC.
    • Ryan C.
    • OncLive. 2022 Dec 21.

    • A systematic method for detecting abnormal mRNA splicing and assessing its clinical impact in individuals undergoing genetic testing for hereditary cancer syndromes.
    • Kamps-Hughes N, Carlton VEH, Fresard L, Osazuwa S, Starks E, Vincent JJ, Albritton S, Nussbaum RL, Nykamp K.
    • J Mol Diagn. 2022 Dec 20:S1525-1578(22)00348-8. doi: 10.1016/j.jmoldx.2022.12.002. Epub ahead of print.

    • Pregnancy-Associated Breast Cancer in BRCA1/2 Carriers: Is Intensified Breast Ultrasound Surveillance Warranted?
    • Fruchtman-Brot H, Mango VL.
    • Acad Radiol. 2022 Dec 19:S1076-6332(22)00595-5. doi: 10.1016/j.acra.2022.11.004. Epub ahead of print.
    • Commentary

    • LitAlert ~~ GeneLit.com

    • Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    • Herzog TJ, Vergote I, Gomella LG, Milenkova T, French T, Tonikian R, Poehlein C, Hussain M.
    • Eur J Cancer. 2023 Jan 1;179:136-146. doi: 10.1016/j.ejca.2022.10.021. Epub ahead of print.

    • Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
    • Magliacane G, Brunetto E, Calzavara S, Bergamini A, Pipitone GB, Marra G, Redegallin M, Grassini G, Rabaiotti E, Taccagni G, Pecciarini L, Carrera P, Mangili G, Doglioni C, Cangi MG.
    • Cancers (Basel). 2022 Dec 21;15(1):43. doi: 10.3390/cancers15010043.

    • Fertility Preferences and Practices Among Young Women With Breast Cancer: Germline Genetic Carriers Versus Non-carriers.
    • Lewinsohn R, Zheng Y, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Peppercorn J, Borges VF, Come S, Snow C, Ginsburg ES, Partridge AH.
    • Clin Breast Cancer. 2022 Dec 21:S1526-8209(22)00290-7. doi: 10.1016/j.clbc.2022.12.012. Epub ahead of print.

    Related:

    •• Identifier: NCT01468246: The Young Women's Breast Cancer Study (HOHO). (ClinicalTrials.gov . Accessed 2022 Dec 21.)

    • European Commission Approves Olaparib Plus Abiraterone and Prednisone/Prednisolone for mCRPC.
    • Ryan C.
    • OncLive. 2022 Dec 21.

    • A systematic method for detecting abnormal mRNA splicing and assessing its clinical impact in individuals undergoing genetic testing for hereditary cancer syndromes.
    • Kamps-Hughes N, Carlton VEH, Fresard L, Osazuwa S, Starks E, Vincent JJ, Albritton S, Nussbaum RL, Nykamp K.
    • J Mol Diagn. 2022 Dec 20:S1525-1578(22)00348-8. doi: 10.1016/j.jmoldx.2022.12.002. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Genetic testing in privately insured women with surgically treated breast cancer.
    • Dinan MA, Pitafi S, Greenup RA, Long JB, Gross CP.
    • Breast Cancer Res Treat. 2022 Dec 21. doi: 10.1007/s10549-022-06829-4. Epub ahead of print.

    • CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    • Lu X, He Y, Johnston RL, Nanayakarra D, Sankarasubramanian S, Lopez JA, Friedlander M, Kalimutho M, Hooper JD, Raninga PV, Khanna KK.
    • J Exp Clin Cancer Res. 2022 Dec 21;41(1):355. doi: 10.1186/s13046-022-02570-4.

    • LitAlert ~~ GeneLit.com

    • Development and validation of genome-wide polygenic risk scores for predicting breast cancer incidence in Japanese females: a population-based case-cohort study.
    • Ohbe H, Hachiya T, Yamaji T, Nakano S, Miyamoto Y, Sutoh Y, Otsuka-Yamasaki Y, Shimizu A, Yasunaga H, Sawada N, Inoue M, Tsugane S, Iwasaki M; for the Japan Public Health Center-based Prospective Study Group.
    • Breast Cancer Res Treat. 2022 Dec 20. doi: 10.1007/s10549-022-06843-6. Epub ahead of print.

    • Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.
    • Abdel-Razeq H, Al-Azzam K, Elemian S, Abu-Fares H, Abu Sheikha A, Bani Hani H, Bater R, Sharaf B, Heald B, Esplin ED, Nielsen SM, Alkyam M, Abujamous L, Al-Attary A.
    • Mol Genet Genomic Med. 2022 Dec 19:e2125. doi: 10.1002/mgg3.2125. Epub ahead of print.

    • Deep Interactive Learning-based ovarian cancer segmentation of H&E-stained whole slide images to study morphological patterns of BRCA mutation.
    • Ho DJ, Chui MH, Vanderbilt CM, Jung J, Robson ME, Park CS, Roh J, Fuchs TJ.
    • J Pathol Inform. 2022 Nov 26 [eCollection 2023];14:100160. doi: 10.1016/j.jpi.2022.100160.

    • LitAlert ~~ GeneLit.com

    • Development and Psychometric Evaluation of Healthcare Access Measures among Women with Ovarian Cancer.
    • Akinyemiju T, Joshi A, Deveaux A, Wilson LE, Chen D, Meernik C, Bevel M, Gathings J, Fish L, Barrett N, Worthy V, Boyce X, Martin K, Robinson C, Pisu M, Liang M, Potosky A, Huang B, Ward K, Schymura MJ, Berchuck A, Reeve BB.
    • Cancers (Basel). 2022 Dec 19;14(24):6266. doi: 10.3390/cancers14246266.

    • Two unrelated cases with biallelic CHEK2 variants:a novel condition with constitutional chromosomal instability?
    • Bottillo I, Savino E, Majore S, Mulargia C, Valiante M, Ferraris A, Rossi V, Svegliati F, Ciccone MP, Brusco F, Grammatico B, Di Giacomo G, Bargiacchi S, D'Angelantonio D, Grammatico P.
    • Eur J Hum Genet. 2022 Dec 19. doi: 10.1038/s41431-022-01270-z. Epub ahead of print.
    • Case report

    • Psychological factors and the uptake of preventative measures in BRCA1/2 pathogenic variant carriers: results of a prospective cohort study.
    • Dick J, Tüchler A, Brédart A, Vitinius F, Wassermann K, Rhiem K, Schmutzler RK.
    • Hered Cancer Clin Pract. 2022 Dec 19;20(1):38. doi: 10.1186/s13053-022-00244-y.

    • Dr. Rimel on the Importance of BRCA and HRD Testing in Ovarian Cancer.
    • Rimel BJ.
    • OncLive. OncLive TV. 2022 Dec 19.

    • Informational needs of individuals from BRCA-harboring families: a systematic review and content analysis.
    • Park SY, Kim Y, Kim S, Katapodi MC.
    • Genet Med. 2022 Dec 18:S1098-3600(22)01068-1. doi: 10.1016/j.gim.2022.100001. Epub ahead of print.

    • Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations.
    • Kuzbari Z, Bandlamudi C, Loveday C, Garrett A, Mehine M, George A, Hanson H, Snape K, Kulkarni A, Allen S, Jezdic S, Ferrandino R, Westphalen CB, Castro E, Rodon J, Mateo J, Burghel GJ, Berger MF, Mandelker D, Turnbull C.
    • Ann Oncol. 2022 Dec 15:S0923-7534(22)04771-8. doi: 10.1016/j.annonc.2022.12.003. Epub ahead of print.

    • Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature.
    • Lee CL, Holter S, Borgida A, Dodd A, Ramotar S, Grant R, Wasson K, Elimova E, Jang RW, Moore M, Kim TK, Khalili K, Moulton CA, Gallinger S, O'Kane GM, Knox JJ.
    • World J Gastroenterol. 2022 Dec 7;28(45):6421-6432. doi: 10.3748/wjg.v28.i45.6421.

    • LitAlert ~~ GeneLit.com

    • Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets.
    • Alatise KL, Gardner S, Alexander-Bryant A.
    • Cancers (Basel). 2022 Dec 18;14(24):6246. doi: 10.3390/cancers14246246.

    • Penetrance of Gastric Adenocarcinoma Susceptibility Genes: A Systematic Review.
    • Hosseini S, Acar A, Sen M, Meeder K, Singh P, Yin K, Sutton JM, Hughes K.
    • Ann Surg Oncol. 2022 Dec 17. doi: 10.1245/s10434-022-12829-x. Epub ahead of print.
    • Review

    • LitAlert ~~ GeneLit.com

    • Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma.
    • Huffman BM, Ellis H, Jordan AC, Freed-Pastor WA, Perez K, Rubinson DA, Sethi N, Singh H, Surana R, Wolpin BM, Aguirre AJ, Cleary JM.
    • Cancers (Basel). 2022 Dec 16;14(24):6223. doi: 10.3390/cancers14246223.

    • A Comparison of Patients’ and Physicians’ Knowledge and Expectations Regarding Precision Oncology Tests.
    • Dehar N, Abedin T, Tang P, Bebb G, Cheung WY.
    • Curr Oncol. 2022 Dec 16;29(12):9916-9927. doi: 10.3390/curroncol29120780.

    • Individualized Maintenance Niraparib Dosing Confers Favorable OS in Recurrent Ovarian Cancer.
    • Seymour C.
    • OncLive. 2022 Dec 16.

    Related:

    •• Identifier: NCT03705156: Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient. (ClinicalTrials.gov . Accessed 2022 Dec 16.)

    • Cost-effectiveness of PARP inhibitors in malignancies: A systematic review.
    • Ding H, He C, Tong Y, Fang Q, Mi X, Chen L, Xin W, Fang L.
    • PLoS One. 2022 Dec 15;17(12):e0279286. doi: 10.1371/journal.pone.0279286.

    • Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.
    • Cristescu R, Liu XQ, Arreaza G, Chen C, Albright A, Qiu P, Marton MJ.
    • BMC Cancer. 2022 Dec 14;22(1):1310. doi: 10.1186/s12885-022-10197-z.

    • Ovarian cancer mutational processes drive site-specific immune evasion.
    • Vázquez-García I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, Niyazov J, Ruiz AEB, Boehm KM, Bojilova V, Fong CJ, Funnell T, Grewal D, Havasov E, Leung S, Pasha A, Patel DM, Pourmaleki M, Rusk N, Shi H, Vanguri R, Williams MJ, Zhang AW, Broach V, Chi DS, Da Cruz Paula A, Gardner GJ, Kim SH, Lennon M, Long Roche K, Sonoda Y, Zivanovic O, Kundra R, Viale A, Derakhshan FN, Geneslaw L, Issa Bhaloo S, Maroldi A, Nunez R, Pareja F, Stylianou A, Vahdatinia M, Bykov Y, Grisham RN, Liu YL, Lakhman Y, Nikolovski I, Kelly D, Gao J, Schietinger A, Hollmann TJ, Bakhoum SF, Soslow RA, Ellenson LH, Abu-Rustum NR, Aghajanian C, Friedman CF, McPherson A, Weigelt B, Zamarin D, Shah SP.
    • Nature. 2022 Dec 14. doi: 10.1038/s41586-022-05496-1. Epub ahead of print.

    • Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis.
    • Lelong M, Raoul JL, Touchefeu Y, Berthelot JM, Arnolfo P, Matysiak-Budnik T, Senellart H.
    • Clin Case Rep. 2022 Dec 12;10(12):e6718. doi: 10.1002/ccr3.6718.

    • The performance of multi-gene panels for breast/ovarian cancer predisposition.
    • Nunziato M, Luca Scaglione G, Di Maggio F, Nardelli C, Capoluongo E, Salvatore F.
    • Clin Chim Acta. 2022 Dec 12:S0009-8981(22)01409-7. doi: 10.1016/j.cca.2022.12.007. Epub ahead of print.

    • Impact of the 2018 ACR Supplemental Screening Recommendations on MRI Eligibility in Breast Cancer Survivors.
    • Lieberenz J, Levy M, Alvarado R, Paul S, Cobleigh M, Usha L, Stempel L.
    • J Am Coll Radiol. 2022 Dec 11:S1546-1440(22)00895-X. doi: 10.1016/j.jacr.2022.11.010. Epub ahead of print.

    • Understanding cancer genetic risk assessment motivations in a remote tailored risk communication and navigation intervention randomized controlled trial.
    • Le Compte CG, Lu SE, Ani J, McDougall J, Walters ST, Toppmeyer D, Boyce TW, Stroup A, Paddock L, Grumet S, Lin Y, Heidt E, Kinney AY.
    • Health Psychol Behav Med. 2022 Dec 9;10(1):1190-1215. doi: 10.1080/21642850.2022.2150623.

    Related:

    •• Identifier: NCT03326713: Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project (GRACE). (ClinicalTrials.gov . Accessed 2022 Dec 16.)

    • Investigating the presentation of uncertainty in an icon array: A randomized trial.
    • Recchia G, Lawrence ACE, Freeman ALJ.
    • PEC Innov. 2022 Dec;1:None. doi: 10.1016/j.pecinn.2021.100003.

    • LitAlert ~~ GeneLit.com

    • Germline findings in patients with advanced malignancies screened with paired blood–tumour testing for personalised treatment approaches.
    • Roggia C, Armeanu-Ebinger S, Gschwind A, Seibel-Kelemen O, Hertler S, Faust U, Liebmann A, Haack TB, Neumann M, Bonzheim I, Forschner A, Kopp HG, Herster F, Hartkopf A, Bitzer M, Malek NP, Brecht IB, Ruhm K, Möller Y, Löwenheim H, Ossowski S, Rieß OH, Schroeder C.
    • Eur J Cancer. 2023 Jan 1;179:48-55. doi: 10.1016/j.ejca.2022.11.003. Epub ahead of print.

    • Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.
    • Jiao Y, Truong T, Eon-Marchais S, Mebirouk N, Caputo S, Dondon MG, Karimi M, Le Gal D, Beauvallet J, Le Floch É, Dandine-Roulland C, Bacq-Daian D, Olaso R, Albuisson J, Audebert-Bellanger S, Berthet P, Bonadona V, Buecher B, Caron O, Cavaillé M, Chiesa J, Colas C, Collonge-Rame MA, Coupier I, Delnatte C, De Pauw A,Dreyfus H,Fert-Ferrer S, Gauthier-Villars M, Gesta P, Giraud S, Gladieff L, Golmard L, Lasset C, Lejeune-Dumoulin S, Léoné M, Limacher JM, Lortholary A, Luporsi É, Mari V, Maugard CE, Mortemousque I, Mouret-Fourme E, Nambot S, Noguès C, Popovici C, Prieur F, Pujol P, Sevenet N, Sobol H, Toulas C, Uhrhammer N, Vaur D, Venat L, Boland-Augé A, Guénel P, Deleuze JF, Stoppa-Lyonnet D, Andrieu N, Lesueur F.
    • Eur J Cancer. 2023 Jan 1;179:76-86. doi: 10.1016/j.ejca.2022.11.007. Epub ahead of print.

    • Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction.
    • Nourieh M, Vibert R, Saint-Ghislain M, Cyrta J, Vincent-Salomon A.
    • Histopathology. 2023 Jan;82(1):162-169. doi: 10.1111/his.14794.

    • Lessons learned with a longer follow-up from SOLO 1.
    • Paulino E.
    • J Gynecol Oncol. 2023 Jan;34:e29. doi: 10.3802/jgo.2023.34.e29. Epub 2022 Dec 7.

    • Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report.
    • Bian Y, Guan P, Li D, Tan L, Pang H, Wen Q, Chen P, Zhang Z.
    • Front Oncol. 2022 Dec 15;12:1071383. doi: 10.3389/fonc.2022.1071383.

    • FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC.
    • Harris J.
    • OncLive. 2022 Dec 15.

    Related:

    •• Identifier: NCT03732820: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Dec 15.)

    • Evaluation of out-of-pocket pay genetic testing in a publicly funded healthcare system.
    • Grant P, Cook CB, Langlois S, Nuk J, Mung S, Zhang Q; GenCOUNSEL Study, Lynd LD, Austin J, Elliott AM.
    • Clin Genet. 2022 Dec 11. doi: 10.1111/cge.14276. Epub ahead of print.